Table 1.
Characteristics of the participants in the BOLD London Follow up who completed the long protocol.
| Abnormal lung function (N = 68) | Normal lung function (N = 40) | Total (N = 108) | |
|---|---|---|---|
| Age (years), median (IQR) | 58 (51–67) | 60.5 (51–65) | 59 (51–67) |
| Sex (%) | |||
| Females | 40 (59) | 23 (58) | 63 (58) |
| Males | 28 (41) | 17 (42) | 45 (42) |
| Ethnicity (%) | |||
| White | 49 (72) | 36 (90) | 85 (79) |
| Other | 19 (28) | 4 (10) | 23 (21) |
| Height (cm), median (IQR) | 165 (159–171) | 168 (159–174) | 168 (161–175) |
| Body mass index (kg/m2), median (IQR) | 25.7 (23.1–31.6) | 27.8 (24.4–30.7) | 26.4 (23.6–29.8) |
| Pack-years of smoking, median (IQR) | 12.6 (0–31.4) | 1.18 (0–13.5) | 4.7 (0–20.6) |
| TLC (L), median (IQR) | 5.62 (4.84–6.46) | 5.72 (4.77–6.59) | 5.65 (4.76–6.43) |
| FVC (L), median (IQR) | 3.22 (2.54–3.70) | 3.22 (2.91–4.07) | 3.22 (2.72–4.53) |
| FVC % predicted, median (IQR) | 83.5 (75.1–102.2) | 98.1 (89.9–105.0) | 92.0 (78.1–104.0) |
| FEV1 (L/s), median (IQR) | 2.05 (1.60 2.50) | 2.50 (2.24–3.08) | 2.46 (2.04–3.03) |
| FEV1% predicted, median (IQR) | 73.4 (63.8–82.7) | 91.2 (81.8–97.7) | 79.4 (69.9–91.7) |
| Pulse rate (beats/min), median (IQR) | 70 (64–76) | 68 (61–74) | 68 (63–76) |
| Pulse wave velocity (m/s), median (IQR) | 9 (7–11) | 9 (8–12) | 9 (8–11) |
| Systolic blood pressure (mm Hg), median (IQR) | 140 (127–151) | 139 (130–146) | 140 (129–148) |
| Diastolic blood pressure (mm Hg), median (IQR) | 78 (72–81) | 76 (70–82) | 78 (72–82) |
| White blood cell count (x109/L), median (IQR) | 6.35 (5.4–7.3) | 5.6 (5–6.9) | 6.0 (5.1–7.3) |
| HbA1c (%), median (IQR) | 5.65 (5.4–5.9) | 5.6 (5.3–5.7) | 5.6 (5.4–5.8) |
| C-reactive protein (μg/mL), median (IQR) | 1.19 (0.41–3.17) | 0.82 (0.36–2.61) | 1.01 (0.36–2.63) |
| IL-8 (pg/mL), median (IQR) | 4.99 (3.80–6.74) | 5.24 (4.05–6.99) | 5.15 (3.89–6.99) |
| IL-6 (pg/mL), median (IQR) | 1.03 (0.70–1.43) | 0.98 (0.63–1.81) | 1.02 (0.71–1.69) |
| TNF-alpha (pg/mL), median (IQR) | 3.44 (2.37–4.44) | 3.69 (2.52–5.46) | 3.62 (2.43–5.29) |
| MPO (ng/mL), median (IQR) | 0.35 (0.26–0.54) | 0.32 (0.20–0.63) | 0.35 (0.24–0.55) |
| VCAM-1 (ng/mL), median (IQR) | 226.0 (186.4–272.6) | 206.0 (181.0–224.4) | 214.5 (181.0–262.6) |
| ICAM-1 (ng/mL), median (IQR) | 146.6 (120.0–193.3) | 134.7 (112.0–156.6) | 139.0 (112.8–167.2) |
| SAA (μg/mL), median (IQR) | 0.68 (0.41–1.20) | 0.67 (0.45–1.03) | 0.68 (0.41–1.11) |
| MMP-3 (ng/mL), median (IQR) | 11.42 (7.44–16.77) | 12.10 (7.34–15.17) | 11.99 (7.69–18.19) |
| MMP-9 (ng/mL), median (IQR) | 48.46 (32.92–69.33) | 40.65 (26.02–57.88) | 45.43 (29.88–66.05) |
| TIMP-1 (ng/mL), median (IQR) | 28.38 (22.06–34.83) | 26.43 (23.17–31.68) | 26.90 (21.73–33.51) |
IQR, interquartile range. TLC, total lung capacity. FVC, forced vital capacity. FEV1, forced expiratory volume in 1 s. HbA1c, glycated haemoglobin. IL-8, interleukin 8. IL-6, interleukin 6. TNF-alpha, tumour necrosis factor alpha. MPO, myeloperoxidase. VCAM-1, vascular cell adhesion protein 1. ICAM-1, intercellular adhesion molecule 1. SAA, serum amyloid A. MMP-3, matrix metalloproteinase 3. MMP-9, matrix metalloproteinase 9. TIMP-1, tissue inhibitor of metalloproteinase 1.